CN109456301A - 一种含冠醚的hbc化合物及其制备和应用 - Google Patents
一种含冠醚的hbc化合物及其制备和应用 Download PDFInfo
- Publication number
- CN109456301A CN109456301A CN201811230188.3A CN201811230188A CN109456301A CN 109456301 A CN109456301 A CN 109456301A CN 201811230188 A CN201811230188 A CN 201811230188A CN 109456301 A CN109456301 A CN 109456301A
- Authority
- CN
- China
- Prior art keywords
- compound
- crown ether
- hbc
- chiral
- containing crown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 44
- 150000003983 crown ethers Chemical class 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000000463 material Substances 0.000 claims abstract description 32
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 17
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 17
- 238000001338 self-assembly Methods 0.000 claims abstract description 7
- 239000000178 monomer Substances 0.000 claims abstract description 6
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims abstract description 5
- 238000006069 Suzuki reaction reaction Methods 0.000 claims abstract description 3
- QBHWPVJPWQGYDS-UHFFFAOYSA-N hexaphenylbenzene Chemical class C1=CC=CC=C1C(C(=C(C=1C=CC=CC=1)C(C=1C=CC=CC=1)=C1C=2C=CC=CC=2)C=2C=CC=CC=2)=C1C1=CC=CC=C1 QBHWPVJPWQGYDS-UHFFFAOYSA-N 0.000 claims abstract description 3
- 238000007243 oxidative cyclization reaction Methods 0.000 claims abstract description 3
- 239000002243 precursor Substances 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 26
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 150000003863 ammonium salts Chemical class 0.000 claims description 4
- -1 cyano, amino Chemical group 0.000 claims description 4
- 125000004185 ester group Chemical group 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 229910052796 boron Inorganic materials 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- SCHYCRCDRYWPGA-UHFFFAOYSA-N 1-bromo-2-dodecylbenzene Chemical compound CCCCCCCCCCCCC1=CC=CC=C1Br SCHYCRCDRYWPGA-UHFFFAOYSA-N 0.000 claims description 2
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 229910052792 caesium Inorganic materials 0.000 claims description 2
- 238000006555 catalytic reaction Methods 0.000 claims description 2
- FQQOMPOPYZIROF-UHFFFAOYSA-N cyclopenta-2,4-dien-1-one Chemical compound O=C1C=CC=C1 FQQOMPOPYZIROF-UHFFFAOYSA-N 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 150000003242 quaternary ammonium salts Chemical group 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims description 2
- HSJKGGMUJITCBW-UHFFFAOYSA-N 3-hydroxybutanal Chemical compound CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 claims 2
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 238000006482 condensation reaction Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000000926 separation method Methods 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 4
- 239000012620 biological material Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 40
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene chloride Substances ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 34
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- 239000007789 gas Substances 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 17
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 16
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 229940125904 compound 1 Drugs 0.000 description 14
- 238000005160 1H NMR spectroscopy Methods 0.000 description 13
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- 239000003480 eluent Substances 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000002983 circular dichroism Methods 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 230000000171 quenching effect Effects 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- KDKYADYSIPSCCQ-UHFFFAOYSA-N but-1-yne Chemical group CCC#C KDKYADYSIPSCCQ-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 2
- 238000006392 deoxygenation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-SVYQBANQSA-N oxolane-d8 Chemical compound [2H]C1([2H])OC([2H])([2H])C([2H])([2H])C1([2H])[2H] WYURNTSHIVDZCO-SVYQBANQSA-N 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical compound C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- LTLVZQZDXQWLHU-UHFFFAOYSA-N 1-bromo-4-ethynylbenzene Chemical group BrC1=CC=C(C#C)C=C1 LTLVZQZDXQWLHU-UHFFFAOYSA-N 0.000 description 1
- NNZYIABRZZBWQH-UHFFFAOYSA-N 2-bromo-4-methoxy-1-phenylbenzene Chemical group BrC1=CC(OC)=CC=C1C1=CC=CC=C1 NNZYIABRZZBWQH-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 101000738322 Homo sapiens Prothymosin alpha Proteins 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 229910002666 PdCl2 Inorganic materials 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L PdCl2(PPh3)2 Substances [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 102100033632 Tropomyosin alpha-1 chain Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000005575 aldol reaction Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000001142 circular dichroism spectrum Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005518 electrochemistry Effects 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- QRRKXCPLJGPVHN-UHFFFAOYSA-N hexabenzocoronene Chemical compound C12C(C(=C34)C(=C56)C7=C89)=C%10C7=C7C%11=CC=CC7=C8C=CC=C9C5=CC=CC6=C3C=CC=C4C1=CC=CC2=C1C%10=C%11C=CC1 QRRKXCPLJGPVHN-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 229910000474 mercury oxide Inorganic materials 0.000 description 1
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical class [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/38—Separation; Purification; Stabilisation; Use of additives
- C07C227/40—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/18—Metal complexes
- C09K2211/181—Metal complexes of the alkali metals and alkaline earth metals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Materials Engineering (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明涉及一种含冠醚的HBC化合物及其制备和应用,所述化合物的通式为式:I或II。制备:利用取代的六苯基苯中间体与单体进行Suzuki偶联反应得到氧化前驱体,通过三氯化铁对前驱体催化进行Scholl氧化关环,即得目标化合物。本发明可作为优良的自组装单元分子应用于生物材料、选择性分离材料、手性响应材料等领域;原料合成具备方法简单,制备工艺成熟等优点,具有良好的应用前景。
Description
技术领域
本发明属于超分子组装材料及其制备和应用领域,特别涉及一种含冠醚的HBC化合物及其制备和应用。
背景技术
上世纪80年代超分子化学概念的提出到现在,超分子化学经历了迅猛地发展。其中,以有机单分子组装的具有规则组装形貌的超分子材料成为研究热点,其分子设计和材料开发吸引了大量科学家的兴趣。拥有大的π-共轭结构的六苯并蔻(Hexa-peri-hexabenzocoronene,HBC)衍生物受到了青睐,可以通过在芳香核上引入柔性的侧链来赋予HBC衍生物的溶解性和热学性能,对分子合成和后续的功能材料的应用至关重要。HBC衍生物由于具有大的π-共轭体系,易通过本身所拥有的极强的π-π相互堆积作用发生自组装,从而使单分子形成一维的非共价键的超分子结构,二维网状结构和三维纳米结构,这些组装的超分子结构在电化学,物理学,生物学等领域都具有广泛应用。
两亲性的HBC化合物作为一类功能化的HBC化合物由于其潜在应用前景而受到广泛的关注。
现阶段大量的手性组装材料主要通过在分子单元中引入手性中心得到,这种手性中心是不可逆的共价键连接,如日本的Yashima教授通过在高分子链中引入大量的不对称手性中心以得到手性螺旋组装体。但是这种通过共价键引入手性中心的策略,需要进行大量的不对称合成和在组装过程中对其手性进行精准的控制,存在着很大的困难,并且大大降低了效率,我们希望通过非共价键实现这一目的。
发明内容
本发明所要解决的技术问题是提供一种含冠醚的HBC化合物及其制备和应用,以克服通过共价键而实现手性材料制备的难题,我们希望通过冠醚基团的非共价键作用来实现手性材料的制备,这种非共价键键能较弱,使得本发明的手性材料还具有可逆性,大大提高了效率。
本发明的一种含冠醚的HBC(六苯并蔻)化合物,其通式为:
其中R1为各自独立的疏水性长链基团、亲水性长链基团、手性长链基团、酯基、氰基、氨基、芳基、巯基中的一种或几种,R2为H或F,其中n≥1的整数。
所述化合物为:
中的一种,其中n≥1的整数。
所述化合物的冠醚基团与金属、铵盐、氨基酸中的一种或几种络合配位。
所述金属为Li、Na、K、Cs中的一种或几种;铵盐为季铵盐。
所述络合配位后的结构式为:
其中R1为各自独立的疏水性长链基团、亲水性长链基团、手性长链基团、酯基、氰基、氨基、芳基、巯基中的一种或几种,R2为H或F,n≥1的整数。
本发明的一种所述含冠醚的HBC化合物的制备方法,包括:
(1)母体部分以十二烷基溴苯为原料,通过Sonogashira偶联反应,炔基氧化以及羟醛缩合反应合成取代的环戊二烯酮中间体,再利用D-A反应得到取代的六苯基苯中间体I;
(2)冠醚取代的亲水性部分通过冠醚单体与双频哪醇合二硼进行Miyaura反应合成单体II;
(3)利用中间体I与单体II进行Suzuki偶联反应得到氧化前驱体,通过三氯化铁对前驱体催化进行Scholl氧化关环即可得到含冠醚的HBC化合物。
本发明提供一种所述含冠醚的HBC化合物作为自组装单元分子在功能性材料制备、开发中的应用。
本发明提供一种所述含冠醚的HBC化合物在超分子组装材料中的应用。
所述含冠醚的HBC化合物组装形貌对溶剂具有响应性,用于超分子组装材料形貌研究。
本发明提供一种所述含冠醚的HBC化合物在制备手性超分子组装材料中的应用。
所述通过手性客体分子对组装形貌进行诱导制备手性超分子组装材料。
本发明提供一种所述含冠醚的HBC化合物与金属的配位络合在制备不同功能的复合功能材料中的应用。
有益效果
(1)本发明提供了一系列新型含冠醚的HBC化合物合成方法,具备原料合成方法简单,制备工艺成熟等优点;
(2)本发明可作为优良的自组装单元分子应用到新型功能材料开发中;
(3)本发明可通过自身所含冠醚基团与不同金属离子配位,而呈现不同的荧光光谱,用于探针材料研究;
(4)本发明通过与手性氨基酸的可逆的非共价键相互作用,而对手性氨基酸具有刺激响应性,制备具有不同手性的纳米材料,在得到手性材料后,可以通过透析等手段除去手性小分子,可得到外围包围有冠醚结构的手性纳米组装体,用于手性氨基酸的检测,分离等材料,并可循环利用;
(5)本发明中含冠醚基团的HBC化合物,具有良好的溶解性,分子结构具有大的共轭体系,这类化合物可以通过π-π堆积自组装构筑一维、二维和三维超分子结构,并且可以通过分子中冠醚基团与金属离子、铵基离子、氨基酸等基团的配位络合能力,可以广泛的应用于响应性超分子材料、光电材料、手性记忆材料、探针材料等领域,这类含冠醚的HBC化合物可以作为优良的自组装单元分子应用到新型功能超分子材料开发中。
附图说明
图1为实施例7化合物1和实施例14化合物2的MALDI-TOF Mass图;其中(a)化合物1的MALDI–TOF–MS图;(b)化合物2的MALDI–TOF–MS图;
图2为实施例8中化合物1与不同手性氨基酸共组装时的SEM(a,c)和TEM(b,d)图;其中(a)化合物1与L-氨基酸共组装的高分辨扫描电镜图(四氢呋喃:甲醇=1:1);(b)化合物1与L-氨基酸共组装的高分辨透射电镜图(四氢呋喃:甲醇=1:1);(c)化合物1与D-氨基酸共组装的高分辨扫描电镜图(四氢呋喃:甲醇=1:1);(d)化合物1与D-氨基酸共组装的高分辨透射电镜图(四氢呋喃:甲醇=1:1);
图3为实施例8中化合物1与不同手性氨基酸共组装时的圆二色谱图(a)和圆二色谱随加入不同量氨基酸变化图(b);
图4为实施例14中化合物2组装前后紫外吸收光谱图(a)和组装过程紫外吸收光谱变化图(b)。
具体实施方式:
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。此外应理解,在阅读了本发明讲授的内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
实施例1
化合物4的合成
向50mL两口瓶瓶中依次加入3(400mg,1.03mmol),双频哪醇合二硼(313mg,1.23mmol),PdCl2(dppf)(75mg,0.103mmol,10%),KOAc(221mg,2.25mmol,3eq.),Ar气保护下抽换气三次,加入无水DMF(冷冻除氧)(20mL),加热至80℃,反应3小时,停止反应。冷至室温后,CH2Cl2萃取(50mL×3),合并有机相,蒸馏水洗(50mL×3),无水硫酸镁干燥有机相,过滤除去硫酸镁,旋蒸蒸除溶剂,剩余物用硅胶层析柱提纯(洗脱剂:二氯甲烷:甲醇=20:1),得浅黄色油状物:200.41mg,产率61%。1H NMR(600MHz,CDCl3)δ(ppm)7.08(d,J=7.1Hz,2H),6.93(d,J=8.4Hz,1H),4.23(d,J=20.9Hz,4H),3.98(s,4H),3.81(s,4H),3.75(s,4H),3.72(s,4H),1.27(s,12H).13C NMR(150MHz,CDCl3):δ(ppm)148.99,148.22,134.54,119.72,114.23,113.16,70.83,70.82,70.78,70.75,69.71,69.69,69.23,69.12,29.71.MALDI–TOF–MS:Calcd.for C22H35BO8[M+Na]+:m/z=461.23;Found:461.38.
实施例2
化合物6的合成
在250mL两口瓶中加入化合物5(5g,15.36mmol),碘化亚铜(0.293g,1.54mmol),PdCl2(PPh3)2(0.66g,0.9mmol),Ar保护下,抽换气三次,加入DBU(14.24mL),苯(20mL),三甲基乙炔基硅(TMSA,1.1mL)和H2O(60μL),加热至80℃,反应24小时后停止反应冷却至室温。CH2Cl2取三次(30mL×3),合并有机相,该有机相用10%HCl洗,再用饱和NaCl洗,旋转蒸发掉大部分溶剂,加入适量硅胶干法柱层析分离,(洗脱剂:石油醚),得无色透明液体2.1g,产率65%。1H NMR(600MHz,CDCl3):δ(ppm)7.45(d,J=7.3Hz,4H),7.17(d,J=7.2Hz,4H),2.62(d,J=6.6Hz,4H),1.62(s,4H),1.30(d,J=17.1Hz,36H),0.90(d,J=6.5Hz,6H)。13C NMR(150MHz,CDCl3):δ(ppm)143.6,131.8,128.8,121.0,89.3,36.3,36.2,31.6,30.0,29.8,29.8,29.7,29.6,23.1,14.5。MALDI–TOF–MS:Calcd.for C38H58[M+H]+:m/z=514.88;Found:515.01。
实施例3
化合物7的合成
向500mL两口烧瓶中加入6(2.46g,4.79mmol),RuO2(14mg),按比例加入CH3CN/CCl4/H2O=14mL/14mL/21mL,在25℃下搅拌2.5小时,蒸馏除去溶剂,用CH2Cl2萃取(50mL×3),合并有机相,无水硫酸镁干燥有机相,过滤除去硫酸镁,旋蒸蒸除溶剂,剩余物用硅胶层析柱提纯,(洗脱剂:石油醚:二氯甲烷=3:1),得淡黄色固体1.6g,产率85%。1H NMR(600MHz,CDCl3):δ(ppm)7.91(d,J=7.9Hz,4H),7.33(d,J=8.0Hz,4H),2.70(t,J=7.7Hz,4H),1.65(m,4H),1.30(d,J=18.0Hz,36H),0.90(t,J=6.6Hz,6H)。13C NMR(150MHz,CDCl3):δ(ppm)194.8,151.2,131.2,128.8,129.3,36.5,32.2,31.3,29.9,29.8,29.7,29.6,29.5,23.0,14.4。MALDI–TOF–MS:Calcd.for C38H58O2[M+H]+:m/z=546.88;Found:546.98。
实施例4
化合物8的合成
向50mL的圆底烧瓶中加入化合物7(300mg,0.55mmol)和1,3-二苯基丙酮(128mg,0.6mmol),Ar保护下,抽换气三次后,加入1,4-二氧六环15mL,回流后加入1.0M四丁基氢氧化铵的甲醇溶液(0.8mL),反应6min后,加水淬灭反应,蒸馏除去溶剂,用CH2Cl2萃取(50mL×3),合并有机相,无水硫酸镁干燥有机相,过滤除去硫酸镁,旋蒸蒸除溶剂,剩余物用硅胶层析柱提纯(洗脱剂:石油醚:二氯甲烷=4:1),得红褐色固体260mg,产率66%。1HNMR(600MHz,CDCl3):δ(ppm)7.26-7.20(m,10H),6.97(d,J=8.0Hz,4H),6.81(d,J=8.0Hz,4H),2.56(t,J=8.0Hz,4H),1.61-1.53(m,4H),1.32-1.27(m,36H),0.89(t,J=7.0Hz,6H).13C NMR(125MHz,CDCl3):δ(ppm)154.59,143.32,131.00,130.22,130.04,129.26,127.84,127.79,127.14,124.79,35.80,32.00,31.66,31.10,29.79,29.74,29.57,29.45,29.26,22.78,22.74,14.22。MALDI–TOF–MS:Calcd.for C53H68O[M+H]+:m/z=721.11;Found:720.00。
实施例5
化合物9的合成
向50mL的Schlenk瓶中加入化合物8(300mg,0.42mmol)和二(4-溴苯基)乙炔(140mg,0.42mmol),Ar保护下,抽换气三次后,加入二苯醚1.5mL,回流反应16h,冷却后硅胶层析柱提纯,(洗脱剂:石油醚:二氯甲烷=6:1),得白色固体380mg,产率88%。1HNMR(600MHz,CDCl3):δ(ppm)7.00(d,J=8.0Hz,4H),6.85-6.84(m,6H),6.77-6.75(m,4H),6.67-6.59(m,12H),2.32(t,J=7.5Hz,4H),1.41-1.33(m,4H),1.30-1.18(m,32H),1.06(br.,4H),0.86(t,J=7.0Hz,6H).13C NMR(150MHz,CDCl3):δ(ppm)141.1,140.3,140.2,139.4,138.4,137.4,132.9,131.2,131.0,129.9,126.7,126.6,125.2,119.5,35.3,32.0,31.2,29.8,29.7,29.6,29.4,28.9,22.8,14.2。MALDI–TOF–MS:Calcd.for C66H76Br2[M+H]+:m/z=1029.12;Found:1028.07.
实施例6
化合物10的合成
向100mL两口烧瓶中加入9(100mg,0.097mmol,1eq.),5(128mg,0.292mmol,3eq.),2M K2CO3(冷冻除氧)(0.8mL,10eq.),Ar气保护下,加入THF(20mL),回流48h,停止反应。旋蒸除去THF,用CH2Cl2萃取(50mL×3),合并有机相,蒸馏水洗(50mL×3),无水硫酸镁干燥,过滤除去硫酸镁,旋转蒸蒸除溶剂,剩余物用氧化铝层析柱提纯(洗脱剂:三氯甲烷:甲醇=30:1),得浅黄色固体97mg,产率62%。1H NMR(600MHz,CDCl3,):δ(ppm)7.09(d,J=8.3Hz,4H),6.99(d,J=8.3Hz,4H),6.91-6.84(m,16H),6.71(d,J=8.1Hz,4H),6.66(d,J=8.1Hz,4H),4.18-4.12(m,8H),3.94-3.89(m,8H),3.79-3.76(m,8H),3.74-3.72(m,8H),3.69(s,8H),2.37(t,J=7.4Hz,4H),1.41(m,4H),1.31-1.22(m,32H),1.12(m,4H),0.90(t,J=7.0Hz,6H).13C NMR(150MHz,CDCl3):δ(ppm)149.00,148.28,140.84,140.75,140.45,139.70,139.51,139.33,137.90,136.98,134.35,131.92,131.54,131.26,126.60,125.05,124.78,119.62,114.3,112.9,70.82,70.81,70.75,69.67,69.66,69.19,35.32,31.95,31.18,29.75,29.70,29.69,29.54,29.40,28.81,22.71,14.14。MALDI–TOF–MS:Calcd.forC98H122O12[M+Na]+:m/z=1514.89;Found:1515.40。
实施例7
化合物1的合成
向250mL两口瓶中加入化合物10(80mg,0.05mmol),抽换气三次后,在Ar鼓泡状态下加入新蒸二氯甲烷100mL,10分钟后加入三氯化铁(265mg,1.61mmol)的硝基甲烷溶液(1.5mL),室温下反应1小时后,加入大量甲醇淬灭反应,此时有大量黄色沉淀析出,抽滤除去滤液,沉淀用氧化铝柱层析提纯(洗脱剂:三氯甲烷:甲醇=20:1),得金黄色固体52mg,产率65%。1H NMR(600MHz,CDCl3):δ(ppm)8.30(s,2H),8.17(s,2H),8.00(s,2H),7.90(d,J=8.0Hz,2H),7.70(s,4H),7.36(s,2H),7.25-7.15(m,4H),7.07(d,J=8.0Hz,2H),4.39(m,8H),4.12(s,8H),3.94(s,8H),3.87(s,8H),3.82(s,8H),2.66(t,J=7.4Hz,4H),1.74(t,J=7.4Hz,4H),1.48-1.22(m,36H),0.90(t,J=7.0Hz,6H).MALDI–TOF–MS:Calcd.forC98H110O12[M+H]+:m/z=1479.81,Found:1479.25;Calcd.for C98H110O12[M+Na]+:m/z=1501.79,Found:1502.01;Calcd.for C98H110O12[M+K]+:m/z=1517.76;Found:1517.99。
实施例8
化合物1和氨基酸络合物的合成
向5mL样品瓶中加入化合物1(0.5mg),加入四氢呋喃1mL,手性氨基酸的甲醇溶液1mL,在40℃下超声2分钟,完全溶解后室温下静置2小时后。取一滴溶液滴在干净硅片上,喷金,利用场发射扫描电镜进行表征;将其溶液滴在超薄碳膜铜网上,利用场发射透射电镜进行表征;圆二色谱仪测试其溶液手性,电镜图上显示组装体为单一手性,圆二色谱图显示溶液为单一手性(图2,3),证明化合物1和手性氨基酸络合体的形成,再通过分子堆积而形成规整的手性组装体。
化合物1对手性氨基酸类化合物具有高度响应性,能够利用化合物1与不同手性的低浓度氨基酸共组装,从而将氨基酸手性放大,通过圆二色谱测试能够准确无误的判断出氨基酸的手性。并且这种手性螺旋组装体结构稳定,通过透析能够除去络合在冠醚上的氨基酸分子,透析后的螺旋组装体还能够对消旋体系的氨基酸进行手性分离,化合物1可运用在氨基酸手性的检测与分离。
实施例9
化合物12的合成
向100mL两口瓶中加入4-溴-4-甲氧基联苯(2.7g,10.12mmol),DBU(9.2g,60.43mmol),双三苯基膦二氯化钯(425mg),碘化亚铜(191mg),氩气保护下,抽换气三次,加入苯40mL,加入三甲基乙炔基硅(0.71mL),水(70ul),避光条件下加热至60℃反应24h。反应结束后,反应液冷却至室温,旋蒸除去溶剂,加入二氯甲烷分散,抽滤,残渣多次水洗,甲醇洗得到棕色粗产物,后用大量甲苯重结晶得到化合物12为白色固体(1.4g,69%)。1HNMR(600MHz,THF-d8):δ7.56(t,J=8.5Hz,8H),7.50(d,J=8.5Hz,4H),6.93(d,J=8.5Hz,4H),3.76(s,6H).MALDI-TOF-MS:Calcd.for C28H22O2[M+H]+:m/z=390.47;found:390.13。
实施例10
化合物14的合成
将化合物13(1.0g,2.18mmol),碳酸钾(336mg,2.4mmol)加入到50mL两口瓶中,氩气保护下抽换气三次,加入四氢呋喃20mL,加热至80℃,缓慢滴加1-氮杂-18-冠-6(574mg,518mmol)的四氢呋喃溶液(10mL),反应24h。反应结束后,将反应液冷却到室温,直接柱层析提纯(洗脱剂:二氯甲烷:甲醇=15:1),得化合物21为淡黄色液体(996mg,83%)。1H NMR(600MHz,CDCl3):δ(ppm)7.78(d,J=8.0Hz,2H),7.16(d,J=8.0Hz,2H),3.98-3.49(m,30H),3.05(s,6H),2.35(s,3H).13C NMR(150MHz,CDCl3):δ(ppm)143.05,139.49,128.64,126.00,71.09,70.47,70.22,70.15,70.08,69.95,69.68,64.65,55.14,50.34,46.17,43.19,21.31.MALDI-TOF mass:calcd.for C25H43NO10S[M+K]+:m/z=588.67;found:588.89。
实施例11
化合物15的合成
向25mL Schlenk管中加入化合物8(0.72g,1mmol)和12(0.39g,1mmol),氩气保护下抽换气三次,加入二苯醚2mL,沙浴回流16h。反应结束后,将反应液冷却到室温,直接柱层析进行提纯(洗脱剂:石油醚:二氯甲烷=3:1),得化合物15为淡黄色固体(0.98g,90%)。1HNMR(600MHz,CDCl3)δ7.39(d,J=7.0Hz,4H),7.10(d,J=6.8Hz,4H),6.88(d,J=13.4Hz,18H),6.71(d,J=6.7Hz,4H),6.66(d,J=6.7Hz,4H),3.81(s,6H),2.37(t,4H),1.41(t,4H),1.28(m,36H),0.90(t,6H)。MALDI-TOF-MS Calcd.For C80H90O2[M+H]+:m/z=1083.61;found:1083.65。
实施例12
化合物16的合成
向50mL两口瓶中加入化合物15(500mg,0.46mmol),氩气保护下抽换气三次,冰水浴下加入二氯甲烷20mL,加入BBr3(0.48g,1.84mmol),反应液立刻变为黑绿色,避光反应16h。反应结束后,加入饱和氯化钠淬灭反应,CH2Cl2萃取三次(50mL×3),合并有机相,无水MgSO4干燥,旋转除去溶剂,柱层析分离提纯(洗脱剂:二氯甲烷:乙酸乙酯=1:9),得化合物16为白色固体(445mg,92%)。1H NMR(600MHz,CDCl3)δ7.33(d,J=7.7Hz,4H),7.08(d,J=7.6Hz,4H),6.88(d,J=7.6Hz,18H),6.71(d,J=7.6Hz,4H),6.66(d,J=7.6Hz,4H),2.36(t,J=7.3Hz,4H),1.41(t,4H),1.25(m,36H),0.90(t,J=6.4Hz,6H)。13CNMR(150MHz,CDCl3):δ(ppm)154.58,140.75,140.60,140.33,139.64,139.24,139.20,137.80,136.77,133.53,131.82,131.44,131.16,127.84,126.49,126.47,124.91,124.57,115.30,35.37,32.00,31.22,29.80,29.75,29.59,29.45,28.87,22.77,14.20。MALDI-TOF-MSCalcd.ForC78H86O2[M+H]+:m/z=1054.66;found:1054.86。
实施例13
化合物17的合成
将化合物14(260mg,0.47mmol),化合物16(200mg,0.19mmol)和碳酸钾(266mg,1.9mmol)加入到50mL两口瓶中,氩气保护下抽换气三次,加入四氢呋喃20mL,加热至80℃,反应24h。反应结束后,将反应液冷却到室温,直接柱层析提纯(洗脱剂:三氯甲烷:甲醇=10:1),得淡黄色油状物,再将油状物用GPC进行分离提纯,得到化合物17为淡黄色油状物(232mg,68%)。1H NMR(600MHz,CDCl3):δ(ppm)7.37(d,J=8.3Hz,4H),7.08(d,J=8.3Hz,4H),6.92-6.84(m,18H),6.70(d,J=8.3Hz,4H),6.65(d,J=8.3Hz,4H),4.20(m,4H),3.93(m,4H),3.76(m,4H),3.66-3.57(m,48H),2.72-2.57(m,12H),2.36(t,J=7.4Hz,4H),1.43-1.39(m,4H),1.34-1.20(m,32H),1.14-1.08(m,4H),0.90(t,J=6.9Hz,6H).13C NMR(150MHz,CDCl3):δ(ppm)157.73,140.89,140.79,140.42,139.68,139.49,139.35,137.83,136.70,133.52,131.93,131.57,131.28,127.72,126,61,126.58,125.01,124.62,114.81,70.00,69.95,69.69,69.26,69.08,68.41,68.30,68.18,67.67,67.31,54.97,52.98,35.31,31.94,31.17,29.74,29.69,29.68,29.53,29.39,28.81,22.70,14.13。MALDI-TOF-MS:calcd.for C114H156N2O16[M+K]+:m/z=1849.11;found:1849.34。
实施例14
化合物2的合成
将化合物17(93mg,0.052mmol)加入到250mL两口瓶中,氩气鼓泡状态下加入二氯甲烷120mL,15min后加入FeCl3(253mg,1.56mmol)的硝基甲烷(3mL)溶液,反应液立刻变为黑色,并伴随有氯化氢气体产生,反应2h。反应结束后,加入甲醇淬灭反应,并伴随有大量黄色沉淀产生,抽滤除去滤液,固体残渣柱层析进行分离提纯(洗脱剂:热四氢呋喃),收集到产物后再通过THF/MeOH进行再沉淀得到化合物2为黄色固体(46mg,52%)。1HNMR(600MHz,THF-d8,55℃):δ(ppm)8.30(s,2H),8.19(s,2H),8.02(s,2H),7.93(d,J=7.3Hz,2H),7.83(s,2H),7.79(s,2H),7.62(d,J=7.3Hz,4H),7.19(s,2H),7.07(d,J=7.3Hz,4H),4.25(s,4H),3.93(d,J=4.7Hz,4H),3.73(d,J=4.7Hz,4H),3.65(d,J=5.0Hz,4H),3.59-3.50(m,44H),2.78(m,12H),2.72(t,J=8.0Hz,4H),1.76(m,4H),1.34-1.23(m,36H),0.80(t,J=7.0Hz,6H).MALDI-TOF-MS:calcd.for C114H144N2O16[M+H]+:m/z=1799.07,found:1799.24;[M+Na]+:m/z=1821.05,found:1821.22;[M+K]+:m/z=1837.02;found:1837.22。
Claims (10)
1.一种如下通式的含冠醚的HBC化合物:
其中R1为各自独立的疏水性长链基团、亲水性长链基团、手性长链基团、酯基、氰基、氨基、芳基、巯基中的一种或几种,R2为H或F,其中n≥1的整数。
2.根据权利要求1所述化合物,其特征在于,所述化合物为:
中的一种,其中n≥1的整数。
3.根据权利要求1所述化合物,其特征在于,所述化合物的冠醚基团与金属、铵盐、氨基酸中的一种或几种络合配位。
4.根据权利要求3所述化合物,其特征在于,所述金属为Li、Na、K、Cs中的一种或几种;铵盐为季铵盐。
5.根据权利要求3所述化合物,其特征在于,所述络合配位后的结构式为:
其中R1为各自独立的疏水性长链基团、亲水性长链基团、手性长链基团、酯基、氰基、氨基、芳基、巯基中的一种或几种,R2为H或F,n≥1的整数。
6.一种权利要求1所述含冠醚的HBC化合物的制备方法,包括:
(1)母体部分以十二烷基溴苯为原料,通过Sonogashira偶联反应,炔基氧化以及羟醛缩合反应合成取代的环戊二烯酮中间体,再利用D-A反应得到取代的六苯基苯中间体I;
(2)冠醚取代的亲水性部分通过冠醚单体与双频哪醇合二硼进行Miyaura反应合成单体II;
(3)利用中间体I与单体II进行Suzuki偶联反应得到氧化前驱体,通过三氯化铁对前驱体催化进行Scholl氧化关环即可得到含冠醚的HBC化合物。
7.一种权利要求1所述含冠醚的HBC化合物作为自组装单元分子在功能性材料制备中的应用。
8.一种权利要求1所述含冠醚的HBC化合物在超分子组装材料中的应用。
9.一种权利要求1所述含冠醚的HBC化合物在制备手性超分子组装材料中的应用。
10.一种权利要求1所述含冠醚的HBC化合物与金属的配位络合在制备复合功能材料中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811230188.3A CN109456301B (zh) | 2018-10-22 | 2018-10-22 | 一种含冠醚的hbc化合物及其制备和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811230188.3A CN109456301B (zh) | 2018-10-22 | 2018-10-22 | 一种含冠醚的hbc化合物及其制备和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109456301A true CN109456301A (zh) | 2019-03-12 |
CN109456301B CN109456301B (zh) | 2021-07-02 |
Family
ID=65608104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811230188.3A Expired - Fee Related CN109456301B (zh) | 2018-10-22 | 2018-10-22 | 一种含冠醚的hbc化合物及其制备和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109456301B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113248468A (zh) * | 2021-06-28 | 2021-08-13 | 苏州百灵威超精细材料有限公司 | 12-冠醚-4锂盐络合物及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106632737A (zh) * | 2016-11-04 | 2017-05-10 | 南开大学 | 一种全甲基化β‑环糊精修饰的六苯并蔻衍生物的纳米超分子组装体 |
-
2018
- 2018-10-22 CN CN201811230188.3A patent/CN109456301B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106632737A (zh) * | 2016-11-04 | 2017-05-10 | 南开大学 | 一种全甲基化β‑环糊精修饰的六苯并蔻衍生物的纳米超分子组装体 |
Non-Patent Citations (5)
Title |
---|
TAKUYA SHIRAISHI等: "6-Arylcoumarins: Versatile Scaffolds for Fluorescent Sensors", 《NEW JOURNAL OF CHEMISTRY》 * |
尚智慧: "含吡啶基的HBC衍生物的合成及其可控自组装的研究", 《东华大学硕士学位论文》 * |
尚智慧等: "含吡啶基的HBC衍生物的合成", 《广州化工》 * |
曾旺等: "含冠醚的HBC 分子合成及自组装性能研究", 《中国化学会第30届学术年会摘要集-第二十四分会》 * |
胡宇苗等: "新型含炔基吡啶的六苯并蔻衍生物的合成*", 《合成化学》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113248468A (zh) * | 2021-06-28 | 2021-08-13 | 苏州百灵威超精细材料有限公司 | 12-冠醚-4锂盐络合物及其制备方法和应用 |
CN113248468B (zh) * | 2021-06-28 | 2021-10-19 | 苏州百灵威超精细材料有限公司 | 12-冠醚-4锂盐络合物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN109456301B (zh) | 2021-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111995761B (zh) | 一种三联吡啶基过渡金属有机聚合物及其制备方法和在二氧化碳光催化还原中的应用 | |
CN107936262B (zh) | 一种超分子聚合物框架材料的制备及应用 | |
CN110204693B (zh) | 基于三苯胺衍生物的高分子共价有机骨架聚合物及制备方法与应用 | |
CN104530105A (zh) | 一种苯并噻二唑或苯并二噻吩桥联的双氟化硼络合二吡咯甲川衍生物有机染料及其制备方法 | |
CN110156755A (zh) | 四吡啶苯基吡嗪及其制备方法、应用 | |
CN108772027B (zh) | 一种超分子有机凝胶及其金属凝胶的制备和应用 | |
CN112592360A (zh) | 一类两亲性氮杂氟硼二吡咯近红外染料及其制备方法 | |
CN110229315A (zh) | 一种基于苝二酰亚胺的宽带隙共聚物受体材料及其制备方法 | |
CN108997391B (zh) | 一种三聚茚基bodipy-富勒烯星型化合物的制备方法 | |
CN109851809A (zh) | 一种柱[5]芳烃单体及其均聚物及制备方法 | |
CN112480130A (zh) | 大环扩展卟啉化合物及其制备方法 | |
CN109456301A (zh) | 一种含冠醚的hbc化合物及其制备和应用 | |
CN108976252A (zh) | 一种三聚茚基bodipy-香豆素星型化合物的制备方法 | |
Tušek-Božić et al. | Efficient solid-state microwave-promoted complexation of a mixed dioxa-diaza macrocycle with an alkali salt. Synthesis of a sodium ethyl 4-benzeneazophosphonate complex | |
CN103073541A (zh) | 吸电子基团修饰的三苯胺星型材料,其制备方法与用途 | |
CN107674021B (zh) | 鼎状四胺芘及制备方法、鼎状四胺芘薄膜修饰的电极及制备方法 | |
CN109575070B (zh) | 一种上缘全消去下缘全取代的杯芳烃磷酸酯衍生物及其制备方法 | |
CN116693373A (zh) | 一种手性联萘对映大环芳烃及其合成方法和应用 | |
CN101891685A (zh) | 烷基咪唑-l-脯氨酸盐手性离子液体及其制备方法 | |
CN110128455B (zh) | 一种冰片酯基苯乙炔基BODIPY类pH荧光探针的制备方法 | |
CN104031108B (zh) | 一种荧光化合物及其制备方法和利用该荧光化合物制备传感薄膜的方法和应用 | |
CN108675918B (zh) | 一种白皮杉醇的合成方法 | |
Ceyhan et al. | Synthesis, characterization, and electrochemical and electrical properties of a novel ball-type hexanuclear metallophthalo-cyanine, bridged by calix [4] arenes substituted with four hexyl-thiometallophthalocyanines through nitro coupling | |
CN104004508A (zh) | 一种导电性混金属聚合物薄膜材料的制备方法 | |
CN103819479B (zh) | 一种含嘧啶基团刚性共轭大环化合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210702 |